NervGen Pharma Corp. (NGEN.V)
| Previous Close | 2.2100 |
| Open | 2.1900 |
| Bid | 2.1800 x 0 |
| Ask | 2.2100 x 0 |
| Day's Range | 2.1200 - 2.2700 |
| 52 Week Range | 1.2600 - 3.3300 |
| Volume | |
| Avg. Volume | 45,334 |
| Market Cap | 101.965M |
| Beta (5Y Monthly) | 1.89 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3540 |
| Earnings Date | Nov 18, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.53 |
- Newsfile
NervGen Hosting Panel Discussion with Leading Experts at the 2022 Annual Meeting of American Spinal Cord Injury Association (ASIA)
Panel discussion will focus on the successful translation of NervGen's lead compound, NVG-291, from animals to humans Leading spinal cord injury experts on the panel include Drs. Jerry Silver, Monica Perez and James GuestNervGen will also present at the International Investment Forum Vancouver, British Columbia--(Newsfile Corp. - May 16, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing a first-in-class
- Newsfile
NervGen Pharma Receives Approval to Proceed to the Final Dose Cohort in Phase 1 Clinical Trial of NVG-291 and Reports Q1 2022 Results
Safety Review Committee approves proceeding to third and highest dose cohort in multiple ascending dose portion of clinical trial No serious or severe adverse events reported in second dose cohort with NVG-291Successful completion of the second cohort establishes a clear pathway to selecting a dose for upcoming Phase 1b/2 clinical trials Vancouver, British Columbia--(Newsfile Corp. - May 12, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical ...
- Newsfile
NervGen Pharma Appoints Craig Thompson to the Board of Directors
30 years of industry experience from CEO of Nasdaq-listed biotech to Vice President, Marketing at PfizerExperience on 16 development stage products, 15 commercial stage products and numerous pre-clinical assets, in both start-up and large pharmaceutical companiesVancouver, British Columbia--(Newsfile Corp. - April 13, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company developing a first-in-class neuroreparative drug to treat ne
